Researcher:
Kalay, Zeynepgül

Profile Picture
ORCID

Job Title

Master Student

First Name

Zeynepgül

Last Name

Kalay

Name

Name Variants

Kalay, Zeynepgül

Email Address

Birth Date

Filters

20222

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.2e51fb07-f156-4e04-ba60-81daa361348d

Search Results

Now showing 1 - 2 of 2
  • Placeholder
    PublicationMetadata only
    A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections
    (Springer, 2022) N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Department of Industrial Engineering; N/A; Demirlenk, Yusuf Mert; Gücer, Lal Sude; Uçku, Duygu; Tanrıöver, Cem; Akyol, Merve; Kalay, Zeynepgül; Barçın, Erinç; Akcan, Rüştü Emre; Can, Füsun; Gönen, Mehmet; Ergönül, Önder; Undergraduate Student; Researcher; Researcher; Undergraduate Student; Undergraduate Student; Undergraduate Student; Master Student; N/A; Undergraduate Student; Faculty Member; Faculty Member; Faculty Member; Department of Industrial Engineering; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Graduate School of Health Sciences; School of Medicine; School of Medicine; School of Medicine; College of Engineering; School of Medicine; N/A; 375775; N/A; N/A; N/A; N/A; N/A; N/A; N/A 237468; 110398
    We aimed to describe the effect of aminoglycosides and tigecycline to reduce the mortality in colistin- and carbapenem-resistant Klebsiella pneumoniae (ColR-CR-Kp) infections. We included the studies with defined outcomes after active or non-active antibiotic treatment of ColR-CR-Kp infections. The active treatment was defined as adequate antibiotic use for at least 3 days (72 h) after the diagnosis of ColR-CR-Kp infection by culture. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the checklist of PRISMA 2020 was applied. Crude and adjusted odds ratios (OR) with 95% confidence interval (CI) were calculated and pooled in the random effects model. Adding aminoglycosides to the existing treatment regimen reduced overall mortality significantly (OR 0.34, 95% CI 0.20-0.58). Overall mortality was 34% in patients treated with aminoglycoside-combined regimens and was 60% in patients treated with non-aminoglycoside regimens. Treatment with tigecycline is not found to reduce mortality (OR: 0.76, 95% CI: 0.47-1.23). Our results suggest that aminoglycoside addition to the existing regimen of colistin- and carbapenem-resistant Klebsiella pneumoniae infections reduces mortality significantly.
  • Thumbnail Image
    PublicationOpen Access
    SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
    (Oxford University Press (OUP), 2022) Ortiz, Alberto; Yau, Kevin; Cherney, David Z. I.; Kalay, Zeynepgül; Şahin, Özgün Ekin; Çöpür, Sidar; Danacı, Senem; Kanbay, Mehmet; Researcher; Faculty Member; Graduate School of Health Sciences; School of Medicine; N/A; N/A; 368625; N/A; 110580
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria. Lay Summary Sodium-glucose cotransporter-2 (SGLT-2) inhibitors might be a promising agent in non-diabetic kidney patients with proteinuria. Lowering proteinuria may help to improve kidney disease patients' outcome by slowing kidney disease progression and decreasing the risk of new cardiovascular events.